JP2022554395A5 - - Google Patents
Info
- Publication number
- JP2022554395A5 JP2022554395A5 JP2022526337A JP2022526337A JP2022554395A5 JP 2022554395 A5 JP2022554395 A5 JP 2022554395A5 JP 2022526337 A JP2022526337 A JP 2022526337A JP 2022526337 A JP2022526337 A JP 2022526337A JP 2022554395 A5 JP2022554395 A5 JP 2022554395A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- tcr
- cancer
- peptide
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962932751P | 2019-11-08 | 2019-11-08 | |
| US62/932,751 | 2019-11-08 | ||
| US201962934914P | 2019-11-13 | 2019-11-13 | |
| US62/934,914 | 2019-11-13 | ||
| PCT/US2020/059476 WO2021092436A1 (en) | 2019-11-08 | 2020-11-06 | Identification of splicing-derived antigens for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022554395A JP2022554395A (ja) | 2022-12-28 |
| JP2022554395A5 true JP2022554395A5 (https=) | 2023-11-14 |
Family
ID=75849568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022526337A Pending JP2022554395A (ja) | 2019-11-08 | 2020-11-06 | がんを処置するためのスプライシング由来抗原の同定 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220380937A1 (https=) |
| EP (1) | EP4055182A4 (https=) |
| JP (1) | JP2022554395A (https=) |
| CN (1) | CN115968406A (https=) |
| WO (1) | WO2021092436A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020144021A1 (en) * | 2019-01-09 | 2020-07-16 | British Telecommunications Public Limited Company | Anomalous behaviour detection in a distributed transactional database |
| JP2023513605A (ja) * | 2020-02-14 | 2023-03-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | がんを処置するためのスプライシング由来抗原を含む組成物および方法 |
| CN118475597A (zh) * | 2021-10-25 | 2024-08-09 | 加利福尼亚大学董事会 | 用于治疗胶质母细胞瘤的方法和组合物 |
| EP4201954A1 (en) * | 2021-12-22 | 2023-06-28 | Christian-Albrechts-Universität zu Kiel | Proteins and t-cells involved in chronic inflammatory diseases |
| CN119343369A (zh) * | 2022-05-04 | 2025-01-21 | 德国癌症研究中心公共法律基金会 | 源自t细胞受体的结合多肽 |
| CN114891885A (zh) * | 2022-05-04 | 2022-08-12 | 重庆大学附属肿瘤医院 | Hdhd5-as1长链非编码rna水平检测试剂在制备卵巢癌干性诊断试剂中的应用 |
| US20260069690A1 (en) * | 2022-08-26 | 2026-03-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Novel cd4+ tumor infiltrating lymphocytes for the treatment of cancer |
| WO2024155630A2 (en) * | 2023-01-17 | 2024-07-25 | The Regents Of The University Of California | Therapeutic polynucleotides encoding t cell receptor (tcr) alpha chain polypeptides and/or tcr beta chain polypeptides |
| WO2025050009A2 (en) * | 2023-09-01 | 2025-03-06 | Children's Hospital Medical Center | Identification of targets for immunotherapy in melanoma using splicing-derived neoantigens |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2448109A1 (en) * | 2001-05-25 | 2002-12-05 | Thomas Jefferson University | Alternative splice forms of proteins as basis for multiple therapeutic modalities |
| WO2013151665A2 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| EP2983702A2 (en) * | 2013-04-07 | 2016-02-17 | The Broad Institute, Inc. | Compositions and methods for personalized neoplasia vaccines |
| KR101503341B1 (ko) * | 2014-03-12 | 2015-03-18 | 국립암센터 | 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법 |
| US10335471B2 (en) * | 2015-08-28 | 2019-07-02 | Immatics Biotechnologies Gmbh | Method for treating cancer with activated T cells |
| EP4576103A3 (en) * | 2017-10-10 | 2025-08-27 | Gritstone bio, Inc. | Neoantigen identification using hotspots |
| JP2023513605A (ja) * | 2020-02-14 | 2023-03-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | がんを処置するためのスプライシング由来抗原を含む組成物および方法 |
-
2020
- 2020-11-06 WO PCT/US2020/059476 patent/WO2021092436A1/en not_active Ceased
- 2020-11-06 EP EP20884088.4A patent/EP4055182A4/en active Pending
- 2020-11-06 CN CN202080092216.9A patent/CN115968406A/zh active Pending
- 2020-11-06 US US17/775,198 patent/US20220380937A1/en active Pending
- 2020-11-06 JP JP2022526337A patent/JP2022554395A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022554395A5 (https=) | ||
| Chandran et al. | T cell receptor‐based cancer immunotherapy: emerging efficacy and pathways of resistance | |
| JP7792249B2 (ja) | 結合ドメイン | |
| JP7068459B2 (ja) | Ｎｙｅｓｏ ｔｃｒ | |
| Schooten et al. | MAGE-A antigens as targets for cancer immunotherapy | |
| JP2024156654A (ja) | 新規操作ｔ細胞受容体およびそれを使用した免疫療法 | |
| JP6639233B2 (ja) | Ｍａｇｅ−ａ１を認識する高結合活性結合分子 | |
| JP2021521776A (ja) | Ｍａｇｅ−ｂ２特異性を有するｔ細胞受容体およびその使用 | |
| CA3188978A1 (en) | Compositions and methods for in vivo generation of car expressing cells | |
| Xiong et al. | CD200 checkpoint reversal: a novel approach to immunotherapy | |
| JP2020533962A5 (https=) | ||
| JP2021528046A5 (https=) | ||
| WO2023078305A1 (zh) | 表达免疫检查点抑制剂的超级dc及其用途 | |
| CN111826353A (zh) | 调节t细胞功能和反应的方法 | |
| Han et al. | Chimeric antigen receptor modified T-cells for cancer treatment | |
| JP2024144409A (ja) | がん幹細胞特異的抗体 | |
| JP2021525068A (ja) | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ２表面発現の遮断およびキメラ抗原受容体の発現 | |
| JP2024515646A5 (https=) | ||
| Garber et al. | Adoptive T-cell therapy for Leukemia | |
| KR102904082B1 (ko) | 항종양제 및 그 평가방법 | |
| JP2021045150A5 (https=) | ||
| CN111448209B (zh) | 新型改造t细胞受体及其免疫治疗的应用 | |
| JP2022554349A5 (https=) | ||
| JP7669546B2 (ja) | がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法 | |
| JP2024526836A5 (https=) |